We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings
Read MoreHide Full Article
Wall Street analysts expect Thermo Fisher Scientific (TMO - Free Report) to post quarterly earnings of $6.40 per share in its upcoming report, which indicates a year-over-year increase of 10.5%. Revenues are expected to be $11.92 billion, up 7.2% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Laboratory Products and Biopharma Services' reaching $6.56 billion. The estimate points to a change of +9.9% from the year-ago quarter.
The consensus estimate for 'Revenues- Specialty Diagnostics' stands at $1.14 billion. The estimate points to a change of -3% from the year-ago quarter.
Analysts forecast 'Revenues- Life Sciences Solutions' to reach $2.85 billion. The estimate indicates a change of +10.3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Analytical Instruments' should arrive at $1.95 billion. The estimate indicates a change of +2.8% from the prior-year quarter.
The consensus among analysts is that 'Revenue Growth - Organic' will reach 4.2%. Compared to the current estimate, the company reported 3.0% in the same quarter of the previous year.
Thermo Fisher shares have witnessed a change of +5.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), TMO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings
Wall Street analysts expect Thermo Fisher Scientific (TMO - Free Report) to post quarterly earnings of $6.40 per share in its upcoming report, which indicates a year-over-year increase of 10.5%. Revenues are expected to be $11.92 billion, up 7.2% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Laboratory Products and Biopharma Services' reaching $6.56 billion. The estimate points to a change of +9.9% from the year-ago quarter.
The consensus estimate for 'Revenues- Specialty Diagnostics' stands at $1.14 billion. The estimate points to a change of -3% from the year-ago quarter.
Analysts forecast 'Revenues- Life Sciences Solutions' to reach $2.85 billion. The estimate indicates a change of +10.3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Analytical Instruments' should arrive at $1.95 billion. The estimate indicates a change of +2.8% from the prior-year quarter.
The consensus among analysts is that 'Revenue Growth - Organic' will reach 4.2%. Compared to the current estimate, the company reported 3.0% in the same quarter of the previous year.
View all Key Company Metrics for Thermo Fisher here>>>Thermo Fisher shares have witnessed a change of +5.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), TMO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .